Salute e Benessere

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

In the case of pelareorep, an intravenously delivered immunotherapy agent developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), the case is getting stronger for it to one day become a treatment for multiple cancers, including most prominently pancreatic cancer. Near the end of 2022, the FDA granted pelareorep a Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) after it demonstrated some optimistic results. Now Oncolytics is continuing to move its…
PR Newswire
09/05/2024

Spatial Genomics Market to be Worth $3.23 Billion by 2031 - Exclusive Report by…

Spatial genomics involves exploring genomics (comprising total DNA and RNA), transcriptomics (RNA transcripts), and epigenomics (molecular compounds) profiling methods to acquire information within a spatial context conducted within intact tissue. This approach aids in establishing a molecular link between genotypes and phenotypes. The significance of spatial genomics arises from the intricate three-dimensional structure of the human body, which plays a crucial role in our molecular physiology…
PR Newswire
09/05/2024

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation…

The FDA ruling sees our upright technology gain 510k status* and clearance to offer the equipment to healthcare providers to treat their patients across the United States with immediate effect. The FDA ruling sees our upright technology gain510kstatus* and clearance to offer the equipment to healthcare providers to treat their patients acrossthe United Stateswith immediate effect. The patient positioning system enables cancer patients to receive radiation treatment seated in an...
PR Newswire
09/05/2024

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology…

The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities."We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery," said Steve Lavezoli, Vice President…
Nasdaq GlobeNewswire
09/05/2024

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024…

AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host aconference call and webcastto discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877)...
Nasdaq GlobeNewswire
09/05/2024

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™…

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the…
PR Newswire
09/05/2024

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare…

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' websiteir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for...
Nasdaq GlobeNewswire
09/05/2024

Persán beats its invoicing record and reaches 811 million euros

The growth of the company, presided over by Concha Yoldi and with Antonio Somé as CEO, is explained by the increase in sales of all its product categories. In this way it has strengthened its leadership in home care at a European level and has increased its market share in the personal care sector. The company's internationalisation plan, starting in 2019, has contributed to this progress, facilitating the arrival of its products on five continents. The growth of the company, presided over by...
PR Newswire
09/05/2024

mAbxience Appoints Jurgen Van Broeck as New CEO

Jurgen joined mAbxience with nearly two decades of extensive experience in the healthcare sector, including significant roles at multinational corporations such as Merck and Mundipharma. His expertise has been particularly impactful in the launch of the first immunology biosimilar across multiple regions, in driving substantial in- and out-licensing deals and steering commercial operations in multiple regions. Jurgen joined mAbxience with nearly two decades of extensive experience in the...
PR Newswire
09/05/2024

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of…

The review, entitled "Unlocking Cancer Vaccine Potential: What are the Key Factors?", was an invited contribution from the editorial team at HVI for inclusion in their special edition on cancer vaccines. The Company co-authored the review in close collaboration with senior academics from the University of Oxford's cancer vaccine programme. The article describes the history of cancer vaccine development, the impact of the SARS-CoV-2 pandemic on vaccine immunology, and the hurdles that…
PR Newswire
09/05/2024

Commit Biologics launches with €16m seed financing to pioneer complement system…

Commit is a spin-out from Aarhus University in Denmark, which has built a global reputation as a center of excellence in complement system biology over the last three decades. The Company was initially incubated and supported by the BioInnovation Institute in Denmark. Commit is a spin-out fromAarhusUniversity inDenmark, which has built a global reputation as a center of excellence in complement system biology over the last three decades. The Company was initially incubated and...
PR Newswire
09/05/2024

A major advance on stroke at Montpellier University Hospital published in the…

Trial of Thrombectomy for Stroke with a Large Infract of Unrestrited Size, published in the New England Journal of Medicine https://www.nejm.org/ Trial of Thrombectomy for Stroke with a Large Infract of Unrestrited Size, published in the New England Journal of Medicine https://www.nejm.org/ Since mechanical thrombectomy, a technique that aims to restore blood flow in stroke patients who experience sudden occlusion of a brain artery, by removing the blockage with device-based...
PR Newswire
09/05/2024

Press release Biocartis Group NV: Biocartis Group NV provides an update…

BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST Biocartis Group NV provides an update regarding the publication of its annual report and the annual meetingMechelen, Belgium, 09 May 2024– Biocartis Group NV (the " Company ") (Euronext Brussels: BCART), announces today that it has decided to postpone the publication of its 2023 Annual Report, in view of the ongoing preparation of the contemplated voluntary dissolution and...
Nasdaq GlobeNewswire
09/05/2024

Approximately USD 10.8 Million Invested in New Drug Development for Malaria and…

The GHIT Fund will invest approximately JPY 444 million (USD 2.9 million1) in two malaria projects: the development of malaria chemoprevention drug through a partnership among Shionogi & Co., Ltd., Nagasaki University, National Institute of Infectious Diseases, and Medicines for Malaria Venture (MMV), and therapeutic drug development led by Eisai Co., Ltd., the Scripps Research Institute, and International Centre for Genetic Engineering and Biotechnology (ICGEB). The GHIT Fund will invest...
PR Newswire
09/05/2024

Sold out: Registration opens for in-cosmetics Korea 2024

in-cosmetics Korea highlights the significance the region's trends have on a much wider audience; K-Beauty is a market that resonates globally, with its product market size set to grow from $10.87 billion this year to $19.29 billion by 2034[1]. in-cosmetics Korea highlights the significance the region's trends have on a much wider audience; K-Beauty is a market that resonates globally, with its product market size set to grow from$10.87 billionthis year to$19.29 billionby 2034[1]...
PR Newswire
09/05/2024

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U...
Nasdaq GlobeNewswire
08/05/2024

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associatedNameJørgen Bundgaard HansenReason for the notificationPosition/statusMember of the Board of Directors...
Nasdaq GlobeNewswire
08/05/2024

The US Laboratory Developed Tests (LDTs) Market to Contribute $3.08 Billion…

The U.S. Laboratory Developed Tests (LDTs) Market Report Scope The U.S. Laboratory Developed Tests (LDTs) Market Report Scope Personalized medicines are becoming the trademark of cancer treatment. It is a constantly evolving approach based on customized treatments based on individual genetic makeup. The FDA approved 12 personalized medications in 2019 to investigate and address the root causes of the diseases, thus combining precision medicine in clinical care. LDTs play a vital role in...
PR Newswire
08/05/2024

TraceLink Named to 2024 RXinsider Pharmacy500 List

Shabbir Dahod, President and CEO of TraceLink, expressed his enthusiasm for this accolade: "Our recognition in the Pharmacy500 highlights TraceLink's dedication to transforming the pharmacy supply chain with cutting-edge technology. Our comprehensive solutions are crafted to help pharmacies adapt to the ever-changing needs of healthcare, enhancing both their operational efficiency and the quality of care they provide." Shabbir Dahod, President and CEO of TraceLink, expressed his…
PR Newswire
08/05/2024

Q3 2023/24 - First sale of the XM30 completed

ANNOUNCEMENT NO. 262 Trading statement for Q3 2023/24 (1 January - 31 March 2024) First sale of the XM30 completedRevenue declined by 6% in the third quarter of 2023/24 to DKK 98.9 million from DKK 105.4 million in the year-earlier period. The development reflected continued growth in sales of consumables and services, set off by declining sales of instruments as customers continued to show restraint in purchasing new instruments. EBITDA fell to DKK 43.1 million in the third...
Nasdaq GlobeNewswire
08/05/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 8 May 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...
Nasdaq GlobeNewswire
08/05/2024

Algae Products Market for Cosmetics to Reach $1.10 Billion by 2031 - Exclusive…

The growth of the algae products market for cosmetics is driven by the growing cosmetics industry, increasing consumer preference for cruelty-free and vegan cosmetics, and rising awareness regarding the health benefits of organic cosmetic products. However, the complexities in algae production and the lack of R&D activities in underdeveloped countries restrain the growth of this market. The growth of the algae products market for cosmetics is driven by the growing cosmetics industry…
PR Newswire
08/05/2024

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by…

Electrosurgery refers to the use of surgical devices that are used to control bleeding and rapidly dissect soft tissues. Electrosurgery employs high-frequency electrical current to cut, coagulate, desiccate, and fulgurate tissue. This can be achieved using either monopolar or bipolar instruments. This can be performed using either monopolar or bipolar energy in conjunction with a specialized instrument. Electrosurgical procedures find application in a wide range of surgeries, including…
PR Newswire
08/05/2024

Liquid Biopsy Market Worth $11.3 billion | MarketsandMarkets™.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "Liquid Biopsy Market" 406 - Tables 56 - Figures 343 - Pages Liquid Biopsy Market Scope: In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment. Based on product & service,...
PR Newswire
08/05/2024
Altri  Comunicati